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Summary
Background.— The European trial on Reduction Of cardiac events with perindopril in patients
with stable coronary Artery disease (EUROPA) demonstrated the beneﬁts of perindopril with
respect to secondary prevention of cardiovascular risk in patients with stable coronary artery
disease.
Aims.— To describe the clinical effects of perindopril in a subpopulation of patients fromSecondary
prevention;
Myocardial
infarction;
EUROPA with a history of myocardial infarction and/or revascularization.
Patients and methods.— Of the 12,218 patients in the EUROPA study, 10,962 had a history of
myocardial infarction and/or revascularization. In this EUROPA subpopulation, 7910 patients had
a history of myocardial infarction and 6709 had a history of revascularization. Patients were
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conversion de
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Prévention
cardiovasculaire ;
Prévention
secondaire ;
Infarctus du
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myocardique
Conclusions.— Les résultats de cette étude conﬁrment les bénéﬁces d’une dose élevée
d’inhibiteur de l’enzyme de conversion pour la prévention secondaire des risques cardiovas-
vec u
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bbreviations
CE Angiotensin-converting enzyme
ABG Coronary artery bypass graft
AD Coronary artery disease
I Myocardial infarction
CI Percutaneous coronary intervention
RR Relative risk reduction
ntroduction
AD remains one of the leading causes of cardiovascu-
ar mortality [1]. However, over recent years, its impact
n morbidity and mortality has decreased due to major
dvances in the management of acute coronary syndromes,
urgical techniques for myocardial revascularization (CABG
rPCI) and secondary prevention. The basis of treatment
or the prevention of recurrence of major cardiovascular
vents has been the use of combinations of antiplatelet
rugs, beta-blockers (in the case of history of MI) and
tatins. More recently, various studies have demonstrated
he beneﬁts of ACE inhibitors for secondary prevention
f
c
e
C
rn antécédent d’infarctus et/ou de revascularisation.
s droits réservés.
n stable CAD. Four major clinical trials have been pub-
ished in this ﬁeld [2—5]. These trials were followed by
hree meta-analyses [6—8] in more than 33,000 subjects,
hich conﬁrmed the importance of ACE inhibitors for sec-
ndary prevention in stable CAD. ACE inhibitors were found
o signiﬁcantly reduce total mortality by approximately
5%, cardiovascular mortality by approximately 20% and the
ccurrence of MI by 18 to 20%. These results were due essen-
ially to the effects of two ACE inhibitors — ramipril and
erindopril.
The Food and Drug Administration and the European
edicines Agency currently recommend perindopril for
table CAD patients with a history of MI and/or revascu-
arization. Although the results for the subpopulation of
atients with a history of revascularization in the Euro-
ean trial on Reduction Of cardiac events with Perindopril
n patients with stable coronary Artery disease (EUROPA)
ave been published previously [9], this is not the caseM. E. Bertrand et al.
randomized to treatment with perindopril 8mg/day or placebo. The primary endpoint was a
composite of cardiovascular mortality, myocardial infarction and resuscitated cardiac arrest.
Results.— After a mean follow-up of 4.2 years, treatment with perindopril 8mg/day was asso-
ciated with a 22.4% reduction in the primary endpoint compared with placebo (p < 0.001) in
patients with a history of myocardial infarction. Patients with a history of myocardial revascu-
larization showed a 17.3% reduction in the primary endpoint with perindopril versus placebo
(p < 0.05). In the combined population of patients with a history of myocardial infarction and/or
revascularization, treatment with perindopril produced a 22.4% reduction in the primary end-
point compared with placebo (p < 0.001).
Conclusions.— This study conﬁrms the beneﬁts of a high dose of angiotensin-converting enzyme
inhibitor for the secondary prevention of cardiovascular risk among patients with a history of
myocardial infarction and/or revascularization.
© 2008 Elsevier Masson SAS. All rights reserved.
Résumé
Objectifs.— L’étude EUROPA a démontré les bénéﬁces du perindopril dans le cadre de la préven-
tion secondaire du risque cardiovasculaire chez les patients avec une athérosclérose coronaire
stable. Le but de cet article est de rapporter les principaux résultats d’un sous-groupe de
l’étude EUROPA chez les patients avec un antécédent d’infarctus du myocarde et/ou de revas-
cularisation myocardique.
Patients et méthodes.— Parmi les 12 218 patients de l’étude EUROPA, 10 902 avaient un antécé-
dent d’infarctus du myocarde (n = 7910) et/ou de revascularisation myocardique (n = 6709).
Cette population a été randomisée en deux groupes, l’un recevant 8mg/j de périndopril et
le second recevant un placebo. L’objectif primaire combinait la mortalité cardiovasculaire,
l’infarctus myocardique ou un arrêt cardiaque récupéré.
Résultats.— Avec un suivi moyen de 4,2 ans, on note que la prescription de perindopril (8mg/j)
chez les patients avec un antécédent d’infarctus du myocarde détermine une réduction sig-
niﬁcative de l’objectif principal : 22,4 % (p < 0,001). Cette réduction est de 17,3 % (p = 0,035)
chez les patients ayant fait l’objet d’une revascularisation myocardique. Elle est de 22,4 %
chez les patients ayant fait l’objet d’un infarctus du myocarde et/ou d’une revascularisation
myocardique.or patients with a history of MI. The aim of this arti-
le, which is a post-hoc analysis, is to describe the clinical
ffects of perindopril on the combined subpopulations of
AD patients from EUROPA with a history of MI and/or
evascularization.
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a signiﬁcant beneﬁt in terms of the primary endpoint (RRRAngiotensin-converting enzyme inhibition with perindopril
Patients and methods
Study population
The EUROPA methodology has been described elsewhere in
detail [3]. Brieﬂy, the trial enrolled 12,218men and women
greater than or equal to 18 years of age, with documented
evidence of CAD and without clinical evidence of heart
failure. Evidence of CAD consisted of any of the follow-
ing: history of MI greater than 3months before screening,
revascularization greater than 6months before screening
and stenosis of greater than 70% in at least one of the
major coronary arteries as assessed by coronary angiogra-
phy. Criteria for exclusion from study entry were clinical
signs of heart failure, hypotension, uncontrolled hyperten-
sion, use of ACE inhibitors or angiotensin receptor blockers
within the last month and impaired renal function and/or
serum potassium greater than 5.5mmol/L. In the EUROPA
cohort, 90% of the patients (n = 10,962) had a history of MI
and/or a history of revascularization. This subpopulation can
be classiﬁed into three groups: patients with a history of
MI (n = 7910); patients with a history of revascularization
(n = 6709); and patients with a history of MI and/or revas-
cularization (n = 10,962).
Study design
EUROPA was a multicenter, double-blind, placebo-controlled
trial. EUROPA started with a run-in period during which
patients received perindopril 4mg/day orally each morning
in addition to their normal treatment for 2weeks, followed
by perindopril 8mg/day orally each morning for a further
2weeks if the 4mg dose was well tolerated. Patients greater
than 70 years of age received perindopril 2mg/day in the
ﬁrst week, then 4mg/day in the second week and 8mg/day
in the last 2weeks. At the end of the run-in period, patients
were assigned randomly to treatment with either perindopril
8mg/day or placebo once daily for at least 3 years. Patients
were seen at 3, 6 and 12months, and then every 6months
for the rest of the trial duration.
Study endpoints
The primary endpoint was a composite of cardiovascular
death, non-fatal MI and resuscitated cardiac arrest. The
secondary endpoints were a composite of total mortality,
non-fatal MI, hospitalization for unstable angina and resusci-
tated cardiac arrest; a composite of cardiovascular mortality
and non-fatal MI; and the individual components of these
secondary endpoints plus coronary revascularization, stroke
and admission for heart failure. Diagnosis of MI was based
on the current recommendations of the European Society of
Cardiology and the American College of Cardiology [10]. The
study included four committees, an Executive Committee,
a Steering Committee, a Data and Safety Monitoring Board,
and a Critical Event Committee (for death and MI).Statistical analyses
The log-rank test was used in an intention-to-treat analy-
sis for the time to ﬁrst occurrence of the primary endpoint.
The Kaplan-Meier method was used to analyse distribution
3
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t
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f events over time and the Cox proportional-hazards model
as used to assess risk reduction for the primary and sec-
ndary endpoints. Descriptive statistics are presented for
he baseline population. A p-value of less than 0.05 was
onsidered to be signiﬁcant.
esults
he results for the endpoints are discussed below, grouped
s follows: patients with a history of MI; patients with a
istory of revascularization; and patients with a history of
I and/or revascularization. Within each group there were
o relevant differences in the baseline characteristics of
atients treated with perindopril or placebo (Tables 1—3).
atients with history of MI
mong the patients with a history of MI (n = 7910, mean
ge 59.6± 9.5 years), 46.2% had a history of revascular-
zation and 65.5% were being treated with beta-blockers
Table 1). The cumulative incidence of the primary end-
oint in patients receiving perindopril (n = 3962) or placebo
n = 3948) during the trial is shown in Fig. 1A. At the end of
he trial, there was a signiﬁcant RRR of 22.4% in the primary
ndpoint (p < 0.001); the incidence was 8.9% in the perindo-
ril group versus 11.3% in the placebo group (Table 4).
erindopril also reduced the recurrence of MI signiﬁcantly
ompared with placebo (5.6% versus 7.6%; 27.9% reduction;
= 0.001). Although the incidence of heart failure was low,
here was a signiﬁcant reduction with perindopril compared
ith placebo (1.1% versus 2.2%; 47.6% reduction; p < 0.001).
atients with history of revascularization
mong the patients with previous revascularization
n = 6709), 54.5% also had a history of MI (Table 2). A history
f PCI was noted in 53.3% of patients and a history of
ABG was noted in 53.5% of patients. Thus, over time,
ome patients underwent both procedures. The cumulative
ncidence of the primary endpoint for perindopril (n = 3340)
nd placebo (n = 3369) throughout the trial is shown in
ig. 1B. The incidence of the primary endpoint at the end
f trial was 6.6% in the perindopril group versus 8.0% in
he placebo group (RRR 17.3%; p < 0.05) (Table 4) [9]. The
ncidence of MI was also signiﬁcantly lower with perindopril
ersus placebo (4.6% versus 5.9%; p < 0.05). The incidence
f heart failure was 40.3% lower in the perindopril group
han in the placebo group (0.7% versus 1.2%; p < 0.05).
In this study, 1648 patients with no history of MI under-
ent revascularization with CABG. In this patient subgroup,
erindopril was associated with a tendency to reduce the
rimary endpoint by 18%, although this trend did not reach
tatistical signiﬁcance (p = 0.28). Among the 1585 patients
ith no history of MI who underwent PCI, perindopril showed4.2%; p < 0.05). For the overall group of 3047 patients with
o history of previous MI who underwent revascularization,
here was also a tendency for perindopril to reduce the pri-
ary endpoint by 23%, although this did not reach statistical
igniﬁcance (p = 0.074).
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Table 1 Baseline characteristics of EUROPA patients with a history of myocardial infarction.
Perindopril 8 mg/day (n = 3962) Placebo (n = 3948) All (n = 7910)
Demographics
Age (mean± S.D.) 59.5± 9.6 59.6± 9.5 59.6± 9.5
Women 567 (14.3) 559 (14.2) 1126 (14.2)
History of CAD
Myocardial infarction 3962 (100.0) 3948 (100.0) 7910 (100.0)
Revascularization 1817 (45.9) 1840 (46.6) 3657 (46.2)
PCI 988 (24.9) 998 (25.3) 1986 (25.1)
CABG 970 (24.5) 965 (24.4) 1935 (24.5)
Medical history
Stroke/transient ischaemic attack 127 (3.2) 127 (3.2) 254 (3.2)
Peripheral vascular disease 264 (6.7) 286 (7.2) 550 (7.0)
Hypertensiona 2239 (56.5) 2230 (56.5) 4469 (56.5)
Diabetes 470 (11.9) 530 (13.4) 1000 (12.6)
Hypercholesterolaemia 2478 (62.5) 2420 (61.3) 4898 (61.9)
Previous treatments
Antiplatelet drugs 2528 (91.7) 2531 (92.5) 5059 (92.1)
Beta-blockers 1828 (66.3) 1769 (64.7) 3597 (65.5)
Lipid-lowering drugs 1552 (56.3) 1462 (53.4) 3014 (54.9)
Nitrates 1257 (45.6) 1327 (48.5) 2584 (47.0)
Calcium antagonists 798 (28.9) 770 (28.1) 1568 (28.5)
Diuretics 225 (8.2) 220 (8.0) 445 (8.1)
Values are n (%) unless otherwise indicated. CABG: coronary artery bypass graft; CAD: coronary artery disease: PCI: percutaneous
coronary intervention; S.D.: standard deviation.
a Deﬁned as blood pressure greater than 140/90mmHg or taking antihypertensive therapy.
Table 2 Baseline characteristics of EUROPA patients with a history of revascularization.
Perindopril 8 mg/day (n = 3340) Placebo (n = 3369) All (n = 6709)
Demographics
Age (mean± S.D.) 59.9± 9.2 60.0± 9.0 60.0± 9.1
Women 480 (14.4) 499 (14.8) 979 (14.6)
History of CAD
Myocardial infarction 1817 (54.5) 1840 (54.6) 3657 (54.5)
Revascularization 3340 (100.0) 3369 (100.0) 6709 (100.0)
PCI 1773 (53.1) 1800 (53.4) 3573 (53.3)
CABG 1790 (53.6) 1797 (53.3) 3587 (53.5)
Medical history
Stroke/transient ischaemic attack 128 (3.8) 101 (3.0) 229 (3.4)
Peripheral vascular disease 243 (7.3) 246 (7.3) 489 (7.3)
Hypertensiona 1895 (56.7) 1944 (57.7) 3839 (57.2)
Diabetes 393 (11.8) 423 (12.6) 816 (12.2)
Hypercholesterolaemia 2306 (69.0) 2298 (68.2) 4604 (68.6)
Previous treatments
Antiplatelet drugs 2153 (93.4) 2165 (95.0) 4318 (94.2)
Beta-blockers 1389 (60.3) 1317 (57.8) 2706 (59.0)
Lipid-lowering drugs 1469 (63.7) 1423 (62.4) 2892 (63.1)
Nitrates 782 (33.9) 804 (35.3) 1586 (34.6)
Calcium antagonists 697 (30.2) 709 (31.1) 1406 (30.7)
Diuretics 166 (7.2) 174 (7.6) 340 (7.4)
Values are n (%) unless otherwise indicated. CABG: coronary artery bypass graft; CAD: coronary artery disease: PCI: percutaneous
coronary intervention; S.D.: standard deviation.
a Deﬁned as blood pressure greater than 140/90mmHg or taking antihypertensive therapy.
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Table 3 Baseline characteristics of EUROPA patients with a history of myocardial infarction and/or revascularization.
Perindopril 8 mg/day (n = 5485) Placebo (n = 5477) All (n = 10,962)
Demographics
Age (mean± S.D.) 59.9± 9.4 59.9± 9.3 59.9± 9.4
Women 812 (14.8) 815 (14.9) 1627 (14.8)
History of CAD
Myocardial infarction 3962 (72.3) 3948 (72.1) 7910 (72.2)
Revascularization 3340 (60.9) 3369 (61.5) 6709 (61.2)
PCI 1773 (32.3) 1800 (32.9) 3573 (32.6)
CABG 1790 (32.6) 1797 (32.8) 3587 (32.7)
Medical history
Stroke/transient ischaemic attack 192 (3.5) 181 (3.3) 373 (3.4)
Peripheral vascular disease 374 (6.8) 394 (7.2) 768 (7.0)
Hypertensiona 3126 (57.0) 3167 (57.8) 6293 (57.4)
Diabetes 653 (11.9) 696 (12.7) 1349 (12.3)
Hypercholesterolaemia 3516 (64.1) 3502 (63.9) 7018 (64.0)
Previous treatments
Antiplatelet drugs 5044 (92.0) 5088 (92.9) 10132 (92.4)
Beta-blockers 3437 (62.7) 3372 (61.6) 6809 (62.1)
Lipid-lowering drugs 3120 (56.9) 3097 (56.5) 6217 (56.7)
Nitrates 2322 (42.3) 2345 (42.8) 4667 (42.6)
Calcium antagonists 1690 (30.8) 1669 (30.5) 3359 (30.6)
Diuretics 551 (10.0) 560 (10.2) 1111 (10.1)
Values are n (%) unless otherwise indicated. CABG: coronary artery bypass graft; CAD: coronary artery disease: PCI: percutaneous
coronary intervention; S.D.: standard deviation.
a Deﬁned as blood pressure >140/90mmHg or taking antihypertensive therapy.
Table 4 Incidence and RRR of the primary endpoint, MI and heart failure in three EUROPA patient subgroups: patients
with a history of MI, patients with a history of revascularization and patients with a history of MI and/or revascularization.
Perindopril (%) Placebo (%) RRR (%) (95% CI) p (Cox)
Primary endpoint
History of MI 8.9 11.3 22.4 (10.8, 32.5) < 0.001
History of revascularization 6.6 8.0 17.3 (1.3, 30.8) 0.035
History of MI/revascularization 7.9 10.1 22.4 (12.0, 31.6) < 0.001
Myocardial infarction
History of MI 5.6 7.6 27.9 (14.2, 39.4) 0.001
History of revascularization 4.6 5.9 22.9 (4.9, 37.6) 0.015
History of MI/revascularization 5.1 7.0 28.7 (16.7—08.9) < 0.001
Heart failure
History of MI 1.1 2.2 47.6 (24.8, 63.5) < 0.001
History of revascularization 0.7 1.2 40.3 (2.0, 63.6) 0.041
History of MI/revascularization 1.0 1.7 41.2 (18.0, 57.9) 0.002
isk re
F
w
wCI: conﬁdence interval; MI: myocardial infarction; RRR: relative r
Patients with history of MI and/or
revascularizationAmong the large subpopulation with a history of MI and/or
revascularization (n = 10,962), 72.2% had history of MI and
61.2% had a history of revascularization (Table 3). The cumu-
lative incidence of the primary endpoint during the trial
for perindopril (n = 5485) and placebo (n = 5477) is shown in
(
a
t
i
pduction.
ig. 1C. At the end of the trial, perindopril was associated
ith a lower incidence of the primary endpoint compared
ith placebo (7.9% versus 10.1%; RRR 22.4%; p < 0.001)
Table 4). The total mortality rate was 6.2% with perindopril
nd 6.8% with placebo (p = 0.211). The cardiovascular mor-
ality rates were 3.6 and 4.1%, respectively (p = 0.19). The
ncidence of MI was also signiﬁcantly lower with perindo-
ril compared with placebo (5.1% versus 7.0%; p < 0.001).
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aigure 1. A. Patients with history of MI. B. Patients with history
inally, the incidence of heart failure was 1.7% with placebo
ompared with 1.0% with perindopril (p < 0.005).
mpact of risk factors and associated
ardiovascular treatmentshe beneﬁcial effects of perindopril were independent of
he presence of cardiovascular risk factors at baseline in
ll study groups (Table 5). In the EUROPA subpopulation
ith a history of MI and/or revascularization, the beneﬁt
f perindopril was additional to the effects of secondary
t
p
t
t
cascularization. C. Patients with history of MI or revascularization.
revention with antiplatelet drugs and lipid-lowering drugs
Table 6).
olerability
f the 10,962 EUROPA patients with a history of MI and/or
history of revascularization, 21.5% left the study prema-urely, and in similar proportions in the perindopril and
lacebo groups (Table 7). However, it should be noted that
hese ﬁgures concern patients who were not excluded in
he run-in period. Perindopril treatment was well tolerated
ompared with placebo. The main reason for stopping treat-
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Table 5 Impact of risk factors on the primary endpoint in three EUROPA patient subgroups: patients with a history of
MI, patients with a history of revascularization and patients with a history of MI and/or revascularization.
History of MI History of
revascularization
History of MI and/or
revascularization
RRR (95% CI) p RRR (95% CI) p RRR (95% CI) p
Hypertension 23.3% (8.8, 35.4) 0.003 24.5% (4.8, 40.2) 0.018 22.6% (9.5, 33.8) 0.001
No hypertension 20.7% (−0.7, 37.6) 0.057 5.7% (−24.5, 28.5) 0.680 21.4% (2.9, 36.4) 0.026
Diabetes 23.3% (−4.2, 43.6) 0.090 20.2% (−21.5, 47.6) 0.292 25.5% (1.1, 43.8) 0.042
No diabetes 20.9% (7.5, 32.4) 0.003 16.2% (−1.9, 31.2) 0.077 21.1% (9.2, 31.4) < 0.001
Hypercholesterolaemia 21.2% (4.6, 34.8) 0.014 13.1% (−9.0, 30.8) 0.224 20.1% (5.5, 32.5) 0.009
No hypercholesterolaemia 23.4% (5.8, 37.6) 0.011 23.3% (−2.2, 42.4) 0.070 25.3% (9.7, 38.2) 0.0003
CI: conﬁdence interval; MI: myocardial infarction; RRR: relative risk reduction.
Table 6 Impact of treatment with antiplatelet and lipid-lowering drugs on the primary endpoint in EUROPA patients
with a history of MI and/or revascularization.
Perindopril 8 mg/day Placebo RRR (95% CI) p (Cox)
Na n (%)b Na n (%)b
Patients with a history of MI
and/or revascularization
receiving lipid-lowering
and antiplatelet treatment
2908 184 (6.3) 2928 235 (8.0) 21.7% (5.0, 35.4) 0.013
Patients with a history of MI
and/or revascularization
not receiving lipid-lowering
and antiplatelet treatment
2577 249 (9.7) 2549 318 (12.5) 23.3% (9.4, 35.0) 0.002
CI: conﬁdence interval; MI: myocardial infarction; RRR: relative risk reduction.
a Number of patients in subpopulation.
b Number (%) of patients with primary endpoint.
Table 7 Reasons for premature withdrawal of treat-
ment in the EUROPA subpopulation with a history of MI
and/or revascularization.
Perindopril
8 mg/day
(n = 5485)
Placebo
(n = 5475)
Cough 146 (2.7) 30 (0.5)
Hypotension 49 (0.9) 14 (0.3)
Renal insufﬁciency 15 (0.3) 10 (0.2)
Intolerance (non-speciﬁed) 132 (2.4) 70 (1.3)
Events 339 (6.2) 416 (7.6)
Hypertension 18 (0.3) 40 (0.7)
Discontinuation 234 (4.3) 235 (4.3)
Other reasons 301 (5.5) 309 (5.6)
Lost to follow-up — 1 (0.02)
Total 1234 (22.5) 1125 (20.5)
Values are n (%).
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Ment with perindopril was cough (2.7% versus 0.5% in the
lacebo group). At 3 years, 95.3% of the patients receiving
erindopril and 95.4% of the patients receiving placebo were
till taking the medication; most patients receiving perindo-
ril were still taking the full 8mg/day dose and only 5% had
educed the dose to 4mg/day.
iscussion
he results of this subpopulation analysis of the EUROPA trial
how that treatment with perindopril is associated with a
igniﬁcant 22.4% RRR in the primary endpoint compared with
lacebo (p < 0.001) in patients with a history of MI and/or
evascularization. The RRR in the primary endpoint was
2.4% in patients with a history of MI and 17.3% in patients
ith a history of revascularization (p < 0.001 and p < 0.05,
espectively). The incidence of MI and heart failure was
educed signiﬁcantly with perindopril treatment in all study
roups. These beneﬁcial effects of perindopril were inde-
endent of baseline cardiovascular risk factors, and were
een even with other secondary prevention in CAD, includ-
ng antiplatelet and lipid-lowering agents. The European
edicines Agency and the Food and Drug Administration gave
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n indication for the appropriate use of perindopril in CAD
atients with a history of MI and/or revascularization, and
ur results support this recommendation.
It is interesting to compare the time of study entry with
he timing of any preceding cardiovascular events in these
ubpopulations. Of the 64% of patients with a history of MI,
ne third had had an MI greater than 5 years before study
ntry, 47% had had an MI between 1 and 5 years before study
ntry and the remainder had had an MI between 3months
nd 1 year before study entry. Enrolment in the study was
hus well beyond the acute phase of MI during which vari-
us other trials and meta-analyses have shown clearly the
eneﬁts of ACE inhibitors for patients with left ventricular
ysfunction [11,12].
According to study protocol, revascularized patients
ould only be enlisted if the procedure had been per-
ormed greater than 6months beforehand. A recent study
as shown that the prescription of high-dose quinapril during
he 10 days after CABG was not beneﬁcial and may even have
ad a deleterious effect [13]. This is in contrast with the
linical beneﬁts of perindopril in the revascularized patients
n our study, and may be due to patients being recruited
months after the procedure. However, long-term use of
uinapril in low-risk CAD patients undergoing PCI also failed
o show any beneﬁcial effects [4].
Although patients in this EUROPA substudy were enrolled
f they had had an MI greater than 3months or revascular-
zation greater than 6months before entry into the study,
he secondary prevention beneﬁts obtained suggest that
erindopril should be prescribed as soon as possible after
ither of these events. Indeed, it has been shown clearly
hat target doses of prescribed medication for secondary
revention are maintained closely at the time of the initial
vent during hospitalization, but that this is less true for
medication prescribed some time after the critical event
14].
Finally, the results of this analysis were obtained using a
igh dose of ACE inhibitor (8mg), which was well tolerated.
xperimental trials have shown that the beneﬁcial effects
f ACE inhibitors on atherogenesis and secondary preven-
ion are obtained primarily with high doses. It is impossible
o extrapolate the results of the EUROPA study [3] to lower
oses. As with all clinical studies, the results in terms of
linical efﬁcacy and safety in a large-scale clinical trial can-
ot be transferred to other agents. In conclusion, the results
f this EUROPA substudy conﬁrm the beneﬁts of perindopril
mg/day in patients with a history of MI and/or revascular-
zation.onﬂict of interest
he EUROPA study was funded by Servier. Drs Bertrand,
ox, Remme, Ferrari, and Simoons declare having received
esearch grants and honoraria from Servier.
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